Lv12
60 积分 2024-04-09 加入
Additional Findings of 18 F-AIF-FAPI-42 PET/CT in a Patient With Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma : Comparisons With 18 F-FDG PET/CT
1天前
已完结
A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in CTCL
2个月前
已关闭
Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome
4个月前
已完结
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
4个月前
已完结
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
11个月前
已完结
Causal Assessment of Phenotypic Risk Factors with Keratinocyte Carcinoma
11个月前
已完结
Number needed to test: quantifying risk stratification provided by diagnostic tests and risk predictions
1年前
已完结
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
1年前
已完结
Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations
1年前
已关闭
Abrogation of USP9X Is a Potential Strategy to Decrease PEG10 Levels and Impede Tumor Progression in Cutaneous T-Cell Lymphoma
1年前
已完结